ep revenu well ahead estim ep guidanc boost sizabl strong
oper tax rate benefit plan increas sharehold return dividend hike
repurchas disclos post februari board meet rais pt reflect
ep estim consensu
ep guidanc increas vs prior guidanc
ep rais estim dollar
reflect improv outlook
sale forecast product beat
estim includ hcv humira imbruvica
kaletra sevofluoran lupron combin
forecast product estim includ androgel light duodopa
synthroid combin forecast revenu guidanc
humira growth ou sale cer assum biosimlar
imbruvica ww sale sale mavyret global sale
roughli equal /ou venclexta ww sale guidanc at/
prior forecast revenu estim review
gpm estim sg
forecast forecast net non-op
expens estim tax rate
estim share count estim guidanc
includ gpm vs d/sale sg a/sal
net interest expens tax rate ramp next year
imbruvica ph data cll/sll dlbcl phoenix full data r/
 fl/mzl selen regulatori file dlbcl wm w/rituxan venclexta ph ii
data r/r fl contralto dlbcl caval initi ph mm mainten
 fl dlbcl wm w/imbruvica /eu approv r/r cll w/rrituxan
file aml upadacitinib ph data ra select-compar select-earli
regulatori file initi ph atop dermat gca uc risankizumab
initi ph uc file psoriasi rova-t pivot ph ii top-lin data triniti
sclc file follow ph data net basket trial r/r sclc
w/ipi nivo elagolix ph top-lin data uterin fibroid approv
endometriosi veliparib ph data vela non-sq nsclc
pleas see page report import disclosur
provid long-term guidanc expect humira appear
solid foot forese futur competit posit hepat
segment oncolog compani pipelin promis agent
opportun upward revis sever front stock attract valu
versu group overal much lower-than-expect tax rate add appeal
attribut argu purchas share
updat sharehold return post
rova-t data/fil sclc mid
mavyret nex-gen hcv rollout
elagolix approv endometriosi
humira sale
biosimilar competit
humira biosimilar gain traction
quickli eu and/or launch
especi oncolog
global biopharmaceut compani product use treat rheumatoid
chronic kidney diseas among other humira ra crohn domin
product repres total sale profit also pipelin
compound indic phase ii phase develop
cowen compani
chg total good profit margin profit gross gross profit profit gross gross profit oper foreign exchang gain expens incom expens incom share cowen
cowen compani
reportedour estimatedifferenceproduct exceed line cowen
cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ heavi depend humira sale ep success pipelin
product notabl hepat portfolio success independ compani
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
